Skip to main content
Smart Investors Daily
AI

NASDAQ · AIMDW

Ainos, Inc.

Healthcare · Biotechnology

$0.05

Up+$0.00 (+4.59%)

Updated Oct 10, 2026, 7:53 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
624.86K
P/E ratio
-0.5
Dividend yield
0.00%
52-week range
$0.05 – $0.16
Volume
8.5K
Avg. volume
7.18K

Price performance · AIMDW

AIMDW price history

1M range · 9 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

AIMDW closed at $0.05 after 9 trading sessions, down 39.70% for the selected period.

Last close
$0.05
Period change
-39.70%
Period low
$0.05
Period high
$0.09
Daily close
View OHLC price history
AIMDW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.0501$0.0697$0.043$0.05248.5K
Oct 8, 2026$0.0503$0.0552$0.0501$0.05018.81K
Oct 7, 2026$0.0723$0.0723$0.0505$0.059918.31K
Oct 6, 2026$0.0552$0.0809$0.0551$0.08082.63K
Oct 5, 2026$0.06$0.0601$0.056$0.0562.22K
Sep 25, 2026$0.088$0.088$0.0879$0.08791.36K
Sep 24, 2026$0.0899$0.0994$0.0899$0.096.53K
Sep 22, 2026$0.06$0.089$0.06$0.0745568
Sep 16, 2026$0.08$0.0998$0.074$0.08699.31K

Latest AIMDW news

The latest Smart Investors Daily articles mentioning AIMDW.

AIMDW research

Overview

Company profile and research snapshot.

Company profile

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2025

Ainos Reports Third Quarter 2025 Financial Results

Digital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens. World's first patented commercial AI Nose device launched, advancing SmellTech-as-a-Service adoption. SAN DIEGO, ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.